HER3 and HER2 expression was significantly correlated with gefitinib resistance but not cetuximab in non-small cell lung cancer and head and neck squamous cell carcinoma (HNSCC) [107]. This evidence concerns the gene ERBB3 and head and neck squamous cell carcinoma.